nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2018-22-3-26-32nefr-362Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯORIGINAL ARTICLES. CLINICAL INVESTIGATIONSОЦЕНКА ФАКТОРОВ РИСКА КАРДИОВАСКУЛЯРНЫХ И МЕТАБОЛИЧЕСКИХ НАРУШЕНИЙ У ДЕТЕЙ С НЕФРИТОМ ПРИ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКЕCARDIOMETABOLIC RISK FACTORS IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS, LUPUS NEPHRITISКозыроИ. А.KazyraI. A.

доц. Козыро Инна Александровна, канд мед наук 220116, Беларусь, г. Минск, пр. Дзержинского, д. 83. Учреждение образования «Белорусский государственный медицинский университет», 1-я кафедра детских болезней. Тел.: +375-173-695-761

associate Professor, MD, PhD, Belarussian State Medical University 1st Department of Pediatrics

kozyroia@mail.ruСукалоА. В.SukaloA. V.

проф., д-р мед наук, академик Национальной Академии наук Беларуси 220116, Беларусь, г. Минск, пр. Дзержинского, д. 83. Учреждение образования «Белорусский государственный медицинский университет», 1-я кафедра детских болезней

prof., MD, PhD, DMedSci. Academic of National Balarus Academy of Sciences, Belarussian State Medical University 1st Department of Pediatrics

kozyroia@mail.ruБелорусский государственный медицинский университетБеларусьBelarussian State Medical UniversityBelarus2018120520182232632Copyright © Козыро И.А., Сукало А.В., 20182018Козыро И.А., Сукало А.В.Kazyra I.A., Sukalo A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/362

В оригинальной статье проведена оценка факторов риска раннего развития кардиоваскулярных осложнений у детей с системной красной волчанкой (СКВ), люпус нефритом (ЛН). Показан вклад хронического иммунного воспаления, метаболических нарушений, артериальной гипертензии, поражения сердечной мышцы, утолщения комплекса интима–медиа.

 

This article provides an assessment of risk factors for early development of cardiovascular and metabolic disorders in children with systemic lupus erythematosus (SLE), lupus nephritis (LN). The contribution to the development of early disturbances of immune inflammation, metabolic imbalance, arterial hypertension, left ventricular hypertrophy, carotid intima-media thickness showed.

люпус-нефритдетикардиоваскулярные и метаболические факторы рискаlupuschildrencardiovascular and metabolic risks factorsReferencesQuinlan C, Kary J, Pilkington C et al. The vascular phenotype of children with systemic lupus erythematosus. Pediatr Nephrol 2015; 30(8):1307–1316. doi: 10.1007/s00467-015-3059-9Quinlan C, Kary J, Pilkington C et al. The vascular phenotype of children with systemic lupus erythematosus. Pediatr Nephrol 2015; 30(8):1307–1316. doi: 10.1007/s00467-015-3059-9Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006;5(5):331–337Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006;5(5):331–337Ahmad Y, Shelmerdine J, Bodill H et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 2007;46(6):983–988Ahmad Y, Shelmerdine J, Bodill H et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 2007;46(6):983–988Salgado A, Herrera-Diaz C. Lupus nephritis: an overview of recent findings. Autoimmune Dis 2012; 2012:849684. doi: 10.1155/2012/849684Salgado A, Herrera-Diaz C. Lupus nephritis: an overview of recent findings. Autoimmune Dis 2012; 2012:849684. doi: 10.1155/2012/849684Jordan N, Lutalo PM, D’Cruz DP. Novel therapeutic agents in clinical development for Systemic Lupus Erythematosus. BMC Medicine 2013; 11:120. doi: 10.1186/1741-7015-11-120Jordan N, Lutalo PM, D’Cruz DP. Novel therapeutic agents in clinical development for Systemic Lupus Erythematosus. BMC Medicine 2013; 11:120. doi: 10.1186/1741-7015-11-120Edelbauer M., Kshirsagar S, Riedl M et al. Markers of childhood lupus nephritis indicating disease activity. Pediatr Nephrol 2011; 26 (3):401–410. doi: 10.1007/s00467-010-1720-xEdelbauer M., Kshirsagar S, Riedl M et al. Markers of childhood lupus nephritis indicating disease activity. Pediatr Nephrol 2011; 26 (3):401–410. doi: 10.1007/s00467-010-1720-xAl M, Ng L, Tyrrell P et al. Adipokines as novel biomarkers in paediatric systemic lupus erythematosus. Rheumatology (Oxford) 2009;48(5):497–501. doi: 10.1093/rheumatology/kep030Al M, Ng L, Tyrrell P et al. Adipokines as novel biomarkers in paediatric systemic lupus erythematosus. Rheumatology (Oxford) 2009;48(5):497–501. doi: 10.1093/rheumatology/kep030Deedwania PC, Pedersen TR, DeMicco DA et al. TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol 2016; 1; 222:548–556. doi: 10.1016/j.ijcard.2016.07.201Deedwania PC, Pedersen TR, DeMicco DA et al. TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol 2016; 1; 222:548–556. doi: 10.1016/j.ijcard.2016.07.201Drozdz D1, Kawecka-Jaszcz K. Cardiovascular changes during chronic hypertensive states. Pediatr Nephrol 2014; 29(9): 1507–1516. doi: 10.1007/s00467-013-2614-5Drozdz D1, Kawecka-Jaszcz K. Cardiovascular changes during chronic hypertensive states. Pediatr Nephrol 2014; 29(9): 1507–1516. doi: 10.1007/s00467-013-2614-5Buyon JP, Cohen AP. А highlight from the LUPUS 2014 meeting: eight great ideas. Lupus Sci Med 2015; 2(1): e000087. Published online 2015 Jun 30. doi: 10.1136/lupus-2015-000087Buyon JP, Cohen AP. А highlight from the LUPUS 2014 meeting: eight great ideas. Lupus Sci Med 2015; 2(1): e000087. Published online 2015 Jun 30. doi: 10.1136/lupus-2015-000087Козыро ИА, Сукало АВ. Факторы прогрессирования вторичных гломерулонефритов у детей. Нефрология 2017; 4 (21):68–72 DOI: http://dx.doi.org/10.24884/1561-6274-2017-21-4-73-78Kazyra IA, Sukalo AV. Faktoryi progressirovaniya vtorichnyih glomerulonefritov u detey. Nefrologiya 2017;4 (21): 68–72] DOI: http://dx.doi.org/10.24884/1561-6274-2017-21-4-73-78

The authors declare that there are no conflicts of interest present.